<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03345537</url>
  </required_header>
  <id_info>
    <org_study_id>RC17_0250</org_study_id>
    <nct_id>NCT03345537</nct_id>
  </id_info>
  <brief_title>Initial Clinical Presentation of Inflammatory Optic Neuritis Associated or Not With Autoantibodies Anti-Myelin-oligodendrocyte-glycoprotein</brief_title>
  <acronym>MOG</acronym>
  <official_title>Observational Prospective Multicentered Study Evaluating Initial Clinical Presentation of Inflammatory Optic Neuritis (ON) Associated or Not With Autoantibodies Anti- Myelin-oligodendrocyte-glycoprotein (MOG-Ab)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In eight ophthalmic units, the investigator will include all inflammatory optic neuritis (ON)
      during acute phase and rank them in two groups: 1/ ON with autoantibodies
      anti-myelin-oligodendrocyte-glycoprotein (ON MOG+) 2/ ON MOG-. The investigators will measure
      incidence of MOG-Ab in our prospective population of inflammatory ON. Then the investigator
      will compare clinical and radiological presentation of ON MOG+ versus ON MOG-.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Optic neuritis (ON) have a broad clinical spectrum ranging from a single episode (clinically
      isolated ON) to demyelinating diseases such as multiple sclerosis (MS), Chronic Relapsing
      Inflammatory Optic Neuritis (CRION), acute demyelination encephalomyelitis (ADEM),
      neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD). Myelin
      oligodendrocyte glycoprotein (MOG) is a myelin antigen exclusively expressed on the surface
      of oligodendrocytes and myelin in the central nervous system (CNS). MOG-Ab are associated
      with demyelinating diseases with a good specificity. Using cell-based assays, MOG-Ab were
      rarely found in healthy control and other neurological inflammatory disease. They were mostly
      identified in subgroups of NMO/NMOSD seronegative to auto antibodies against Aquaporin 4
      (anti-AQP4): 8-39%, but also in MS (0-28%) ADEM and idiopathic ON. ON MOG + have a specific
      clinical presentation compare with ON associated with multiple sclerosis (SEP): older
      patient, less female preponderance, more often bilateral, more often optic disc swelling,
      worse initial visual loss, much more often recurrent with severe sequelae. ON MOG+ are more
      similar to ON associated with NMOSD AQP4+ which have some particularities: similar age, clear
      female preponderance, less optic disc swelling, more severe initial visual loss and visual
      sequelae. No prospective study has measured incidence of

      MOG-Ab in population of Inflammatory ON. And no prospective study has ever compared ON MOG+
      with all others inflammatory ON. The purpose of our study is to measure incidence of MOG-Ab
      in population of acute inflammatory ON. All consenting adults with suspicion of ON followed
      in the 8 ophthalmic units who participate will be screened. They will have, as usual,
      clinical follow-up, blood test with MOG-Ab research, encephalic and optic nerves MRI, and
      steroid treatment if necessary. At the end of the acute phase, all patients diagnosed with
      inflammatory ON will be included and rank in 2 groups: 1/ ON with MOG-Ab (ON MOG+) 2/ ON
      without MOG-Ab (ON MOG-). Clinical data will be register at this inclusion visit. There will
      be no additional visit and no intervention. After measuring incidence of MOG-Ab, the
      investigator will compare clinical and radiological data of ON MOG+ and ON MOG-.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2017</start_date>
  <completion_date type="Anticipated">January 19, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 19, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of anti-Myelin-oligodendrocyte-glycoprotein (MOG-ab)</measure>
    <time_frame>the day of inclusion</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Optic Neuritis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non interventional study</intervention_name>
    <description>Non interventional study - only data collected and one blood sample additional</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample (5mL)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Phe patients included will be mostly young adults between 18 and 40 years old, consultant
        in the ophthalmology department of the University Hospital of Nantes for an inflammatory
        optic neuropathy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  legally adult patient

          -  acute inflammatory optic neuritis

          -  consent

        Exclusion Criteria:

          -  Patient under tutorship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Lebranchu, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Lebranchu, Dr</last_name>
    <phone>02 44 76 82 48</phone>
    <email>pierre.lebranchu@chu-nentes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Baptiste Ducloyer, Dr</last_name>
    <email>jeanbaptiste.ducloyer@chu-nantes.fr</email>
  </overall_contact_backup>
  <reference>
    <citation>Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. 2016 Apr;15(4):307-24. doi: 10.1016/j.autrev.2015.12.004. Epub 2015 Dec 17. Review.</citation>
    <PMID>26708342</PMID>
  </reference>
  <reference>
    <citation>Akaishi T, Nakashima I, Takeshita T, Kaneko K, Mugikura S, Sato DK, Takahashi T, Nakazawa T, Aoki M, Fujihara K. Different etiologies and prognoses of optic neuritis in demyelinating diseases. J Neuroimmunol. 2016 Oct 15;299:152-157. doi: 10.1016/j.jneuroim.2016.09.007. Epub 2016 Sep 14.</citation>
    <PMID>27725114</PMID>
  </reference>
  <reference>
    <citation>Ramanathan S, Reddel SW, Henderson A, Parratt JD, Barnett M, Gatt PN, Merheb V, Kumaran RY, Pathmanandavel K, Sinmaz N, Ghadiri M, Yiannikas C, Vucic S, Stewart G, Bleasel AF, Booth D, Fung VS, Dale RC, Brilot F. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2014 Oct 29;1(4):e40. doi: 10.1212/NXI.0000000000000040. eCollection 2014 Dec.</citation>
    <PMID>25364774</PMID>
  </reference>
  <reference>
    <citation>Havla J, Kümpfel T, Schinner R, Spadaro M, Schuh E, Meinl E, Hohlfeld R, Outteryck O. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. J Neurol. 2017 Jan;264(1):139-151. doi: 10.1007/s00415-016-8333-7. Epub 2016 Nov 14.</citation>
    <PMID>27844165</PMID>
  </reference>
  <reference>
    <citation>Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, Nakashima I, Apostolos-Pereira SL, Talim N, Simm RF, Lino AM, Misu T, Leite MI, Aoki M, Fujihara K. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014 Feb 11;82(6):474-81. doi: 10.1212/WNL.0000000000000101. Epub 2014 Jan 10.</citation>
    <PMID>24415568</PMID>
  </reference>
  <reference>
    <citation>Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hümmert MW, Ringelstein M, Trebst C, Winkelmann A, Schwarz A, Buttmann M, Zimmermann H, Kuchling J, Franciotta D, Capobianco M, Siebert E, Lukas C, Korporal-Kuhnke M, Haas J, Fechner K, Brandt AU, Schanda K, Aktas O, Paul F, Reindl M, Wildemann B; in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016 Sep 27;13(1):280.</citation>
    <PMID>27793206</PMID>
  </reference>
  <reference>
    <citation>Höftberger R, Sepulveda M, Armangue T, Blanco Y, Rostásy K, Calvo AC, Olascoaga J, Ramió-Torrentà L, Reindl M, Benito-León J, Casanova B, Arrambide G, Sabater L, Graus F, Dalmau J, Saiz A. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler. 2015 Jun;21(7):866-874. doi: 10.1177/1352458514555785. Epub 2014 Oct 24.</citation>
    <PMID>25344373</PMID>
  </reference>
  <reference>
    <citation>The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol. 1991 Dec;109(12):1673-8.</citation>
    <PMID>1841573</PMID>
  </reference>
  <reference>
    <citation>Stiebel-Kalish H, Lotan I, Brody J, Chodick G, Bialer O, Marignier R, Bach M, Hellmann MA. Retinal Nerve Fiber Layer May Be Better Preserved in MOG-IgG versus AQP4-IgG Optic Neuritis: A Cohort Study. PLoS One. 2017 Jan 26;12(1):e0170847. doi: 10.1371/journal.pone.0170847. eCollection 2017.</citation>
    <PMID>28125740</PMID>
  </reference>
  <reference>
    <citation>Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992 Feb 27;326(9):581-8.</citation>
    <PMID>1734247</PMID>
  </reference>
  <reference>
    <citation>Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler. 2014 Apr;20(4):501-4. doi: 10.1177/1352458513495938. Epub 2013 Aug 28.</citation>
    <PMID>23986097</PMID>
  </reference>
  <reference>
    <citation>Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology. 2008 Jun;115(6):1079-1082.e5. Epub 2007 Nov 5.</citation>
    <PMID>17976727</PMID>
  </reference>
  <reference>
    <citation>Garcia-Martin E, Ara JR, Martin J, Almarcegui C, Dolz I, Vilades E, Gil-Arribas L, Fernandez FJ, Polo V, Larrosa JM, Pablo LE, Satue M. Retinal and Optic Nerve Degeneration in Patients with Multiple Sclerosis Followed up for 5 Years. Ophthalmology. 2017 May;124(5):688-696. doi: 10.1016/j.ophtha.2017.01.005. Epub 2017 Feb 7.</citation>
    <PMID>28187977</PMID>
  </reference>
  <reference>
    <citation>Beck RW, Gal RL, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, Corbett J, Eggenberger E, Goodwin JA, Katz B, Kaufman DI, Keltner JL, Kupersmith MJ, Miller NR, Moke PS, Nazarian S, Orengo-Nania S, Savino PJ, Shults WT, Smith CH, Trobe JD, Wall M, Xing D; Optic Neuritis Study Group. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol. 2004 Jan;137(1):77-83. Erratum in: Am J Ophthalmol. 2004 Aug;138(2):following 321. Am J Ophthalmol. 2004 Apr;137(4):following 793.</citation>
    <PMID>14700647</PMID>
  </reference>
  <reference>
    <citation>Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, Bellmann-Strobl J, Jarius S, Wildemann B, Reindl M, Waldman A, Soelberg K, Asgari N, Ringelstein M, Aktas O, Gross N, Buttmann M, Ach T, Ruprecht K, Paul F, Brandt AU; in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation. 2016 Nov 1;13(1):282.</citation>
    <PMID>27802824</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammatory</keyword>
  <keyword>Optic neuritis</keyword>
  <keyword>autoantibodies anti MOG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuritis</mesh_term>
    <mesh_term>Optic Neuritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Krestin</mesh_term>
    <mesh_term>Autoantibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

